Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL

BEAM-201 Represents First Quadruplex-edited, Allogeneic CAR-T Cell Therapy Candidate in Clinical-stage Development and First Treatment with a Base Editing Candidate in United States CAMBRIDGE,...

Related Keywords

United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Chelcie Lister ,Dan Budwick ,John Evans ,Exchange Commission ,Strategic Communications ,Beam Therapeutics Inc ,Nasdaq ,First Quadruplex Edited ,Clinical Stage Development ,First Treatment ,Base Editing Candidate ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Markets ,